NervGen Pharma
NGEN
45 hedge funds and large institutions have $6.42M invested in NervGen Pharma in 2026 Q1 according to their latest regulatory filings, with 44 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
11,370% more capital invested
Capital invested by funds: $56K → $6.42M (+$6.37M)
4,400% more funds holding
Funds holding: 1 → 45 (+44)
2.1% more ownership
Funds ownership: 0% → 2.1% (+2.1%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PI
PFG Investments
Woodbury,
New York
|
+$871K |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$869K |
| 3 |
Marshall Wace
London,
United Kingdom
|
+$868K |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$745K |
| 5 |
IWC
Integrated Wealth Concepts
Waltham,
Massachusetts
|
+$376K |
Top Sellers
NGEN Hedge Fund Activity: Q1 2026 in Review
45 of the 8,191 institutional investors tracked by Wall St. Rank reported a position in NervGen Pharma (NGEN) for Q1 2026, worth a combined $6.42M — up 11,370% from $56K a quarter earlier.
Buyers outnumbered sellers: 44 funds opened new NGEN positions and 0 closed out — a net gain of 44 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was PFG Investments, opening a new position worth an estimated $871K.
- 45 institutional investors held NervGen Pharma (NGEN) as of Q1 2026, up from 1 in Q4 2025.
- Funds reported $6.42M of NervGen Pharma stock for Q1 2026, up 11,370% quarter-over-quarter.
- 44 funds opened new NervGen Pharma positions in Q1 2026 and 0 closed out, a net change of +44 holders.
- The largest NervGen Pharma buyer in Q1 2026 was PFG Investments, an estimated $871K added.
Based on aggregated 13F filings for Q1 2026.